|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
CTG004311981 |
| 003 |
DE-627 |
| 005 |
20230425170512.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
210507s2021 xx |||||o 00| ||eng c |
| 035 |
|
|
|a (DE-627)CTG004311981
|
| 035 |
|
|
|a (UBBS_Klinische_Studien_WHO)EUCTR2015-000716-18-HU
|
| 035 |
|
|
|a (UBBS_Klinische_Studien_WHO)CCD-05993AB1-03
|
| 035 |
|
|
|a (UBBS_Klinische_Studien_WHO)2015-000716-18-GB
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 245 |
1 |
0 |
|a A 52 week, randomized, double blind, multinational, multicentre, active controlled, 2-arm parallel group trial comparing CHF 5993 100/6/12.5 µg pMDI (fixed combination of extrafine beclometasone dipropionate plus formoterol fumarate plus glycopyrronium bromide) to CHF 1535 100/6 µg pMDI (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) in patients with asthma uncontrolled on medium doses of inhaled corticosteroids in combination with long-acting ß2-agonists - Trimaran
|b A 52 week, randomized, double blind, multinational, multicentre, active controlled, 2-arm parallel group trial comparing CHF 5993 100/6/12.5 µg pMDI (fixed combination of extrafine beclometasone dipropionate plus formoterol fumarate plus glycopyrronium bromide) to CHF 1535 100/6 µg pMDI (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) in patients with asthma uncontrolled on medium doses of inhaled corticosteroids in combination with long-acting ß2-agonists - Trimaran
|
| 264 |
|
1 |
|c 2021
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a Computermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 29-10-2015, Last updated: 2022-11-24
|
| 650 |
|
4 |
|a Medical Condition: Uncontrolled asthma MedDRA version: 20.0Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
|
| 650 |
|
4 |
|a Study Type: Interventional
|
| 650 |
|
4 |
|a Phase: Phase 3
|
| 650 |
|
4 |
|a Recruitment Status: Not yet recruiting
|
| 650 |
|
4 |
|a 610
|
| 773 |
0 |
8 |
|i Enthalten in
|t WHO International Clinical Trials Registry Platform
|g (2021) vom: 21. Dez.
|
| 773 |
1 |
8 |
|g year:2021
|g day:21
|g month:12
|
| 856 |
4 |
0 |
|u https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2015-000716-18
|z kostenfrei
|3 Volltext
|
| 912 |
|
|
|a GBV_CTG
|
| 912 |
|
|
|a SSG-OLC-PHA
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|j 2021
|b 21
|c 12
|
Klinische Studie